Pre-Op SRS Before Surgery for Brain Metastases
Trial Summary
What is the purpose of this trial?
This is a research study to determine if performing stereotactic radiosurgery (SRS) prior to surgical resection of the brain metastasis (tumor) will improve local control, in other words, increase the possibility of total removal of the primary tumor without local recurrence on longterm follow up. This research study will also determine if pre-operative SRS will lower the risk of radionecrosis that is the breakdown of body tissue at the original tumor site, and the development of leptomeningeal disease.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What data supports the effectiveness of the treatment Pre-operative Stereotactic Radiosurgery for brain metastases?
Research suggests that pre-operative stereotactic radiosurgery (SRS) before surgery for brain metastases may reduce the risk of radiation side effects and lower the chance of cancer spreading to the brain's protective layers. It also helps in better targeting the tumor, potentially leading to improved treatment outcomes.12345
Is preoperative stereotactic radiosurgery (SRS) safe for treating brain metastases?
Preoperative SRS for brain metastases is generally considered safe, with studies showing a low risk of radiation necrosis (damage to healthy brain tissue) and leptomeningeal disease (spread of cancer to the lining of the brain). It may offer advantages over postoperative SRS by reducing the volume of healthy brain exposed to radiation and potentially lowering the risk of adverse effects.23678
How is pre-operative stereotactic radiosurgery different from other treatments for brain metastases?
Pre-operative stereotactic radiosurgery (SRS) is unique because it is given before surgery, which helps to better target the tumor and reduce the risk of spreading cancer cells during surgery. This approach can also lower the chance of radiation side effects and improve control over the cancer compared to traditional post-operative treatments.247910
Research Team
Rodney E Wegner, MD
Principal Investigator
AHN Radiation Oncology
Eligibility Criteria
This trial is for adults with solid tumor brain metastases who can consent to treatment, have a Karnofsky Performance Status of ≥70 (meaning they are able to care for themselves), and agree to use contraception. They must be planning surgery for at least one brain metastasis smaller than 5 cm. Those with serious medical or psychiatric illnesses, prior whole-brain radiation, or pregnant women cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Stereotactic Radiosurgery (SRS)
Participants undergo stereotactic radiosurgery using the Elekta Gamma Knife Icon, treated in once daily or every other day 15 minute fractions of 9 Gy for a total dose of 27 Gy in 3 doses
Surgical Resection
Routine surgical resection of the brain metastasis is performed within two weeks after completion of SRS
Follow-up
Participants are monitored for safety and effectiveness after treatment, with MRIs performed and quality of life questionnaires completed
Treatment Details
Interventions
- Pre-operative Stereotactic Radiosurgery
Find a Clinic Near You
Who Is Running the Clinical Trial?
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Lead Sponsor
Elekta Limited
Industry Sponsor